Amperos Health vs Claimable
Two Denials & Appeals vendors, side by side. Facts from public sources; judgments are ours.
At a glance
Derived from public facts · a rough scale, not a ranking
| Amperos Health | Claimable | |
|---|---|---|
| Pricing model | Not published | Per-transaction / per-chart · about $40-50 per appeal, some free |
| Speed to go live | No configuration; working day one | consumer self-serve, appeal drafted in minutes |
| Automation model | Autonomous agents · AI biller calls and works denials | AI copilot · drafts evidence-backed appeal letters |
| Built for | Small practices, Mid-size groups, Billing companies | Small practices, Enterprise systems |
| Security posture | SOC 2 Type I, HIPAA | SOC 2 Type II, HIPAA |
| Company maturity | 3 yrs (est. 2023) | 3 yrs (est. 2023) |
| Financial backing | $20.2M · Series A | $10M · Seed |
| Named customers | None public | None public |
| Published results | Specific numbers public | Specific numbers public |
| Documented integrations | None documented | None documented |
| Third-party validation | None found | None found |
Bottom line
- Pick Amperos if denials and aging A/R are piling up and you want an AI biller chasing claims from day one with no setup project.
- Pick Claimable if patients or one-off denials need fast, cheap, evidence-backed appeals with zero procurement.
Amperos Health
AI biller that works denials by phone and portal
- Founded
- 2023
- HQ
- New York, NY
- Stage
- Series A
- Raised
- $20.2M
What it does
- Calls payers to check status and dispute denials
- Works payer portals for claim follow-up
- Drafts and submits appeals with medical records
- Submits corrected claims
- Denial analytics and root-cause reporting
Where it's strong
- Automates the actual follow-up work, phone calls included, rather than just flagging denials for staff.
- Real volume behind the claims: over 3,000 clinical locations served and roughly $700M in annual recovered revenue across 500,000-plus claims.
- Pairs AI automation with human billing experts for complex claims instead of forcing everything through the model.
What buyers should weigh
- Founded in 2023, so it is still a young vendor for a function that touches core cash flow.
- Named reference customers are not public; ask for references in your specialty and billing system.
- Best fit is denial follow-up and recovery; it is not a full front-to-back RCM platform.
Claimable
AI-generated appeals for denied health insurance claims
- Founded
- 2023
- HQ
- Sacramento, CA
- Stage
- Seed
- Raised
- $10M
What it does
- AI-drafted appeals citing policy terms and medical literature
- Delivery to insurer appeals departments and executives
- Coverage for 28 conditions and 90+ treatments
- Support for 80+ medications including Humira and Dupixent
- Case tracking with most resolved within 10 days
Where it's strong
- Reports roughly 75 to 80% of appeals ending in overturned denials, far above typical patient appeal rates.
- Flat per-case pricing around $50 makes it accessible without a contract or implementation.
- Founding team combines clinical, payer, and VA data science backgrounds, and the escalation tactic of copying executives and regulators gets responses.
What buyers should weigh
- Coverage is limited to a defined list of conditions and treatments, so many denial types are out of scope today.
- The core product is patient-facing; provider and enterprise offerings are newer and less proven at volume.
- It appeals one claim at a time and does not address the upstream documentation or authorization issues driving denials.
Compare against the rest of Denials & Appeals
Deciding between these two?
First Pass tracks Denials & Appeals every week: funding, launches, and what changed since this page was written.